NASDAQ:ANIPANI Pharmaceuticals Stock Price, Forecast & News

ANI Pharmaceuticals' stock was trading at $38.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ANIP stock has decreased by 16.0% and is now trading at $32.17. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ANI Pharmaceuticals.

ANI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for ANI Pharmaceuticals.

ANI Pharmaceuticals Inc (NASDAQ:ANIP) released its quarterly earnings data on Thursday, May, 7th. The specialty pharmaceutical company reported $1.04 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.89 by $0.15. The specialty pharmaceutical company had revenue of $49.77 million for the quarter, compared to analysts' expectations of $49.40 million. ANI Pharmaceuticals had a negative net margin of 0.67% and a positive return on equity of 23.92%. View ANI Pharmaceuticals' earnings history.

ANI Pharmaceuticals updated its FY 2020 Pre-Market earnings guidance on Thursday, February, 27th. The company provided earnings per share (EPS) guidance of 4.46-4.86 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.47. The company issued revenue guidance of $213-223 million, compared to the consensus revenue estimate of $229.15 million.

3 Wall Street analysts have issued twelve-month target prices for ANI Pharmaceuticals' shares. Their forecasts range from $40.00 to $58.00. On average, they expect ANI Pharmaceuticals' share price to reach $49.00 in the next year. This suggests a possible upside of 52.3% from the stock's current price. View analysts' price targets for ANI Pharmaceuticals.

Press coverage about ANIP stock has trended negative on Tuesday, InfoTrie reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ANI Pharmaceuticals earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave news stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutANI Pharmaceuticals.

Some companies that are related to ANI Pharmaceuticals include BELLUS Health (BLUSF), Karyopharm Therapeutics (KPTI), Y-mAbs Therapeutics (YMAB), Intra-Cellular Therapies (ITCI), Akcea Therapeutics (AKCA), Innoviva (INVA), Amneal Pharmaceuticals (AMRX), Passage Bio (ZNTL), Portola Pharmaceuticals (PTLA), INDIVIOR PLC/S (INVVY), Tricida (TCDA), Cytokinetics (CYTK), Supernus Pharmaceuticals (SUPN), ZEALAND PHARMA/S (ZEAL) and MacroGenics (MGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Teva Pharmaceutical Industries (TEVA), Broadcom (AVGO), AbbVie (ABBV), Cisco Systems (CSCO), Intel (INTC) and NXP Semiconductors (NXPI).

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

ANI Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.03%), State Street Corp (2.69%), First Manhattan Co. (2.23%), Invesco Ltd. (2.20%), Global Alpha Capital Management Ltd. (1.80%) and Geode Capital Management LLC (1.13%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, David Nash, James G Marken, Meridian Venture Partners Ii L, Robert W Schrepfer and Thomas Haughey. View institutional ownership trends for ANI Pharmaceuticals.

ANIP stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., BlackRock Inc., Wells Fargo & Company MN, THB Asset Management, Morgan Stanley, New York State Common Retirement Fund, Parametric Portfolio Associates LLC, and State Board of Administration of Florida Retirement System. View insider buying and selling activity for ANI Pharmaceuticals.

ANIP stock was purchased by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Federated Hermes Inc., Foundry Partners LLC, AQR Capital Management LLC, Global Alpha Capital Management Ltd., Pictet Asset Management Ltd., SG Americas Securities LLC, and Acadian Asset Management LLC. Company insiders that have bought ANI Pharmaceuticals stock in the last two years include David Nash, and Thomas Haughey. View insider buying and selling activity for ANI Pharmaceuticals.

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ANIP stock can currently be purchased for approximately $32.17.

ANI Pharmaceuticals has a market capitalization of $389.58 million and generates $206.55 million in revenue each year. The specialty pharmaceutical company earns $6.09 million in net income (profit) each year or $4.46 on an earnings per share basis. ANI Pharmaceuticals employs 299 workers across the globe.

The official website for ANI Pharmaceuticals is www.anipharmaceuticals.com.

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]